Alpelisib for the treatment of HR+HER2-metastatic breast cancer in patients with the PIK3CA mutation: results of the SOLAR-1 study
- 作者: Semiglazova T.Y.1,2, Semiglazov V.V1,3, Klimenko V.V1, Brish N.A1, Alekseeva Y.V1, Klyuge V.A1, Krutov A.A1, Paltuev R.M1, Kasparov B.S1, Krivorotko P.V1,2, Semiglazov V.F1,2
-
隶属关系:
- N.N. Petrov National Medical Research Center of Oncology
- North-Western State Medical University n.a. I.I. Mechnikov
- First Pavlov State Medical University
- 期: 卷 27, 编号 7 (2020)
- 页面: 15-23
- 栏目: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/312712
- DOI: https://doi.org/10.18565/pharmateca.2020.7.15-23
- ID: 312712
如何引用文章
详细
全文:
作者简介
T. Semiglazova
N.N. Petrov National Medical Research Center of Oncology; North-Western State Medical University n.a. I.I. Mechnikov
Email: tsemiglazova@mail.ru
Dr. Sci. (Med.), Associate Professor, Head of the Division - Leading FResearcher at the Scientific Department of Innovative Methods of Therapeutic Oncology and Rehabilitation, Petrov NMRC of Oncology, Professor at the Department of Oncology, North-Western State Medical University n.a. I.I. Mechnikov 68 Leningradskaya str., Pesochny settlment, St. Petersburg 197758, Russian Federation
V. Semiglazov
N.N. Petrov National Medical Research Center of Oncology; First Pavlov State Medical UniversitySt. Petersburg, Russia
V. Klimenko
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
N. Brish
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
Yu. Alekseeva
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
V. Klyuge
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
A. Krutov
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
R. Paltuev
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
B. Kasparov
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
P. Krivorotko
N.N. Petrov National Medical Research Center of Oncology; North-Western State Medical University n.a. I.I. MechnikovSt. Petersburg, Russia
V. Semiglazov
N.N. Petrov National Medical Research Center of Oncology; North-Western State Medical University n.a. I.I. MechnikovSt. Petersburg, Russia
参考
- Cardoso F, et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Ann Oncol. 2018;29:1634-1657. doi: 10.1093/annonc/mdy192.
- Стенина М.Б. и др. RUSSCO#3s2. 2019;9:128-63. [Stenina M.B. et al. RUSSCO#3s2. 2019;9:128-63. (In Russ.)]. doi: 10.18027/2224-5057-2019-9-3s2-128-163.
- Клинические рекомендации. Рак молочной железы 2020. URL: http://cr.rosminzdrav.ru/#!/ recomend/236. Дата обращения: 16.04.2020.
- Tripathy D, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptorpositive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19:904-15. doi: 10.1016/S1470-2045(18)30292-4.
- Seock-Ah Im, et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med. 2019;381:307-16. Doi: 10.1056/ NEJMoa1903765.
- Slamon D. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. J Clin Oncol. 2018;36:2465-72. Doi: 10.1200/ JCO.2018.78.9909.
- Slamon D., et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2020;382:514-24. doi: 10.1056/NEJMoa1911149.
- Rugo H.S., Finn R.S., Dieras V., et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat. 2019;174(3):719-29. doi: 10.1007/s10549-018-05125-4.
- Cristofanilli M., Turner N.C., Bondarenko I., et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptorpositive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, doubleblind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425-39. doi: 10.1016/S1470-2045(15)00613-0.
- Turner N.C., et al. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2018;379:1926-36. Doi: 10.1056/ NEJMoa1810527.
- Johnston, S., Martin, M., Di Leo, A. et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019;5:5. Doi: https://doi.org/10.1038/s41523-018-0097-z.
- Sledge G., et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol. 2020;35:2875-84. Doi: 10.1200/ JCO.2017.73.7585.
- Sledge G.W., Toi M., Neven P, et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncol. 2020;6(1):116-24. Doi: 10.1001/ jamaoncol.2019.4782.
- Gao J., et al. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. Lancet Oncology. 2019;21(2):250-60. Doi: https://doi.org/10.1016/ S1470-2045(19)30804-6.
- Yardley D.A., Noguchi S., Pritchard K.I., et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis [published correction appears in Adv Ther. 2014;31(9):1008-9]. Adv Ther. 2013;30(10):870-84. doi: 10.1007/s12325-013-0060-1
- Piccart M., Hortobagyi G.N., Campone M., et al. Everolimus plus exemestane for hormone-receptorpositive, human epidermal growth factor receptor-2negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol. 2014;25(12):2357-62. doi: 10.1093/annonc/mdu456.
- Goncalves M.D., Hopkins B.D., Cantley L.C. Phosphatidylinositol 3-Kinase, Growth Disorders, and Cancer. N Engl J Med. 2018;379:2052-62. doi: 10.1056/NEJMra1704560.
- Семиглазова Т.Ю., Сорокина И.В. Прогностическое и предиктивное значения мутации гена PIK3CA у больных раком молочной железы. Фарматека. 2019;26(7):10-20.
- Sobhani N., Roviello G., Corona S.P, et al. The prognostic value of PI3K mutational status in breast cancer: A meta-analysis. J Cell Biochem. 2018;119(6):4287-92. doi: 10.1002/jcb.26687.
- Mosele F., et al. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. Ann Oncol. 2020;31(3):377-86. Doi: https:// doi.org/10.1016/j.annonc.2019.11.006.
- Hortobagyi G.N., Chen D., Piccart M., et al. Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. J Clin Oncol. 2016;34(5):419-26. Doi: 10.1200/ JCO.2014.60.1971.
- Neven P., et al. Biomarker analysis by baseline circulating tumor DNA alterations in the MONALEESA-3 study. Cancer Res. 2019;79(4S). doi: 10.1158/1538-7445.SABCS18-PD2-05.
- Campone M., Im S.A., Iwata H., et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2. Eur J Cancer. 2018;103:147-54. Doi: 10.1016/j. ejca.2018.08.002.
- Di Leo A., et al. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptorpositive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19:87-100. Doi: 10.1016/ S1470-2045(17)30688-5.
- Baselga J., et al. Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER. J Clin Oncol. 2018;36(18_suppl):LBA1006-LBA1006. doi: 10.1200/JCO.2018.36.18_suppl.LBA1006.
- Juric D., Janku F., Rodon J., et al. Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial. JAMA Oncol. 2019;5(2):e184475. doi: 10.1001/jamaoncol.2018.4475.
- Andre F, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019;380:1929-40. Doi: 10.1056/ NEJMoa1813904.
- Juric D., et al. Alpelisib (ALP) with fulvestrant (FUL) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Primary or secondary resistance to prior endocrine therapy (ET) in the SOLAR-1 trial. J Clin Oncol. 2019;37(15_suppl):1038-38. Doi: 10.1200/ JCO.2019.37.15_suppl.1038.
- Состояние онкологической помощи населению России в 2018 г. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2019, 236 с.
- Поддубная И.В., Колядина И.В., Калашников Н.Д. и др. Популяционный «портрет» рака молочной железы в России: анализ данных российского регистра. Современная онкология. 20!5;!7(1):25-9.
- Jacquet E, et al. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients. Eur J Cancer. 2018;95:93-101. doi: 10.1016/j.ejca.2018.03.013